When asked about HF treatment in this disease most of them had chosen either loop diuretic (75%) or mineralocorticoid receptor antagonists (60%), but a significant proportion stated they would treat these patients with betablockers (46%) and angiotensin converting enzyme inhibitors (57%) (Figure 5). The gene discussed is NR3C2; the disease is hydrops fetalis.